Literature DB >> 20695729

Antinociceptive and anti-inflammatory effects of Costus spicatus in experimental animals.

Lucindo J Quintans Júnior1, Marília T Santana, Mônica S Melo, Damião P de Sousa, Ivandilson S Santos, Rosana S Siqueira, Tamires C Lima, Gabriela O Silveira, Angelo R Antoniolli, Luciano A A Ribeiro, Márcio R V Santos.   

Abstract

CONTEXT: Costus spicatus Swartz (Costaceae), commonly called "cana-do-brejo'" in Brazil's northeast, is a medicinal plant found in wet coastal forests. In folk medicine an infusion of the aerial parts is taken to treat inflammation and pain.
OBJECTIVE: The methanol extract obtained from the leaves of Costus spicatus (MECs) was evaluated for antinociceptive and anti-inflammatory activities.
METHODS: Analgesic and anti-inflammatory activities were studied by measuring nociception through acetic acid, formalin, and hot-plate tests, while inflammation was induced by carrageenan. All experiments were conducted with experimental animals. RESULTS AND DISCUSSION: Following oral administration, MECs (100, 200, and 400 mg/kg) significantly reduced the number of writhes (52.8, 43.1, and 55.3%, respectively) in the writhing test and the number of paw licks during phase 1 (61.9, 54.1, and 92.1%) and phase 2 (62.5, 82.9, and 98.1%, all doses) during the formalin test when compared to the control group animals. The reaction time during the hot-plate test was increased significantly and was dose-dependent, whereas pretreatment with naloxone rigorously reduced the analgesic potential of MECs, which suggested participation of the opioid system in the modulation of pain induced by MECs. Such results were unlikely to be provoked by motor abnormality, as MECs-treated mice did not exhibit any performance alteration during the Rota-rod test. The administration of 200 and 400 mg/ kg (i.p.) of MECs exhibited an anti-inflammatory effect during the carrageenan test, which was based on interference with inflammatory mediator synthesis.
CONCLUSION: We conclude that MECs has antinociceptive and anti-inflammatory activities in rodents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695729     DOI: 10.3109/13880200903501822

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  4 in total

1.  Costus root granules improve ulcerative colitis through regulation of TGF-β mediation of the PI3K/AKT signaling pathway.

Authors:  Xiaohong Wang; Dan Li; Yong Zhang; Shuang Wu; Fang Tang
Journal:  Exp Ther Med       Date:  2018-03-09       Impact factor: 2.447

2.  Linalool and linalool complexed in β-cyclodextrin produce anti-hyperalgesic activity and increase Fos protein expression in animal model for fibromyalgia.

Authors:  Simone S Nascimento; Enilton A Camargo; Josimari M DeSantana; Adriano A S Araújo; Paula P Menezes; Waldecy Lucca-Júnior; Ricardo L C Albuquerque-Júnior; Leonardo R Bonjardim; Lucindo J Quintans-Júnior
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-24       Impact factor: 3.000

3.  Cyclodextrin-complexed Ocimum basilicum leaves essential oil increases Fos protein expression in the central nervous system and produce an antihyperalgesic effect in animal models for fibromyalgia.

Authors:  Simone S Nascimento; Adriano A S Araújo; Renan G Brito; Mairim R Serafini; Paula P Menezes; Josimari M DeSantana; Waldecy Lucca; Pericles B Alves; Arie F Blank; Rita C M Oliveira; Aldeidia P Oliveira; Ricardo L C Albuquerque; Jackson R G S Almeida; Lucindo J Quintans
Journal:  Int J Mol Sci       Date:  2014-12-29       Impact factor: 5.923

4.  Atheroprotective Properties of Costus spicatus (Jacq.) Sw. in Female Rats.

Authors:  Bethânia Rosa Lorençone; Lucas Pires Guarnier; Rhanany Alan Calloi Palozi; Paulo Vitor Moreira Romão; Aline Aparecida Macedo Marques; Lislaine Maria Klider; Roosevelt Isaias Carvalho Souza; Ariany Carvalho Dos Santos; Cleide Adriane Signor Tirloni; Nadla Soares Cassemiro; Denise Brentan Silva; Jane Manfron Budel; Arquimedes Gasparotto Junior
Journal:  Life (Basel)       Date:  2021-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.